MarketCap
Facebook
X
Telegram
Predictive Oncology Balance Sheet 2025-2001 | POAI
Brief overview of Predictive Oncology 's assets and capital
The review uses the five latest available annual reports between 2021 and 2025.
The asset base progressed from $43.8 million to $52.9 million, equal to +20.8% overall and about 4.8% per year.
Asset growth of +20.8% came with a +47.5% rise in liabilities. Financial leverage became more prominent.
Equity accounts for 90.2% of assets. Against the initial 92%, the capital position looks resilient.
Negative net debt of -$9.2 million means cash holdings are larger than debt obligations.
Cash equals 20.4% of the balance sheet, compared with 64.4% five periods ago. This is the readily available cushion.
Retained earnings remain negative at -$413.5 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Overall assessment
Predictive Oncology 's financial position is more positive than negative: the funding mix is workable, although the cushion is not unlimited.
Annual Balance Sheet Predictive Oncology
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-9.23 M | 1.5 M | -5.84 M | -21.9 M | -27.3 M | 3.75 M | 5.37 M | 1.47 M | -766 K | -1.76 M | -4.86 M | 921 K | 178 K | 1.16 M | 1.56 M | 997 K | - | - | - | - | - | - | - | - | - |
Long Term Debt |
904 K | 1.56 M | 2.11 M | 86.1 K | 240 K | - | - | - | - | - | - | - | - | 89.3 K | 630 K | 1.01 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
654 K | 555 K | 407 K | 94.2 K | 640 K | 597 K | 459 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 236 K | 270 K | - | - | 310 K | - | 214 K | 343 K | 258 K | 796 K | - | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
4.27 M | 3.59 M | 3.95 M | 3.88 M | 3.24 M | 9.34 M | 10.9 M | 3.66 M | 932 K | 1.57 M | 1.52 M | 6.2 M | 3.47 M | 3.41 M | 2.35 M | 1.33 M | 480 K | - | - | - | - | - | - | - | - |
Total Liabilities |
5.17 M | 5.18 M | 6.15 M | 3.97 M | 3.51 M | 10.4 M | 11.1 M | 3.66 M | 932 K | 1.88 M | 1.52 M | 6.42 M | 3.81 M | 3.67 M | 3.15 M | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
144 K | 224 K | 270 K | 602 K | 187 K | 53 K | 40.4 K | 23.1 K | 6.66 K | 8 K | 5 K | 5 K | 69 K | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-414 M | -180 M | -168 M | -154 M | -128 M | - | -82.5 M | -63.1 M | -54.8 M | -47 M | -40.5 M | -35.6 M | -28.7 M | -19.3 M | -11.9 M | - | 6.65 K | - | - | - | - | - | - | - | - |
Total Assets |
52.9 M | 4.97 M | 14.4 M | 25.7 M | 43.8 M | 13.1 M | 22.4 M | 3.71 M | 3.62 M | 2.81 M | 5.63 M | 901 K | 593 K | 370 K | 446 K | 166 K | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
10.8 M | 612 K | 8.36 M | 22.1 M | 28.2 M | 678 K | 151 K | 162 K | 766 K | 1.76 M | 4.86 M | 16.4 K | 102 K | 13.1 K | 123 K | 9.38 K | 16.6 K | 464 K | - | - | - | - | - | - | - |
Book Value |
47.7 M | -203 K | 8.27 M | 21.8 M | 40.3 M | 2.64 M | 11.2 M | 53.5 K | 2.69 M | 924 K | 4.11 M | -5.52 M | -3.22 M | -3.3 M | -2.7 M | 166 K | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
47.7 M | -203 K | 8.27 M | 21.8 M | 40.3 M | 2.64 M | 11.2 M | 53.5 K | 2.69 M | 924 K | 4.11 M | -5.52 M | -3.22 M | -3.3 M | -2.7 M | -2.19 M | -2.34 M | -309 K | -712 K | -515 K | -302 K | -181 K | -91.1 K | -36.1 K | - |
All numbers in USD currency
Quarterly Balance Sheet Predictive Oncology
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
725 K | 1.08 M | 1.24 M | 1.41 M | 1.56 M | 1.7 M | 1.86 M | 2.03 M | 2.13 M | 2.34 M | - | - | 86.1 K | - | - | - | 240 K | - | - | - | 845 K | 845 K | 845 K | 845 K | 270 K | 270 K | 270 K | 270 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 89.3 K | 89.3 K | 89.3 K | 89.3 K | 630 K | 630 K | 630 K | 630 K |
Total Liabilities |
4.95 M | 80.6 M | 5.09 M | 6.01 M | 5.18 M | 5.53 M | 6.49 M | 6.55 M | 6.15 M | 6.52 M | 6.26 M | 6.51 M | 3.97 M | 3.57 M | 2.96 M | 2.88 M | 3.51 M | 3.41 M | 3.82 M | 4.11 M | 10.4 M | 10.4 M | 10.4 M | 10.4 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 3.66 M | 3.66 M | 3.66 M | 3.66 M | 932 K | 932 K | 932 K | 932 K | 1.88 M | 1.88 M | 1.88 M | 1.88 M | 1.52 M | 1.52 M | 1.52 M | 1.52 M | 6.42 M | 6.42 M | 6.42 M | 6.42 M | 3.81 M | 3.81 M | 3.81 M | 3.81 M | 3.67 M | 3.67 M | - | - | - | - | - | - |
Deferred Revenue |
786 K | 147 K | 149 K | 152 K | 224 K | 257 K | 270 K | 304 K | 302 K | 375 K | 628 K | 639 K | 602 K | 495 K | 531 K | 183 K | 187 K | 153 K | 154 K | 154 K | 53 K | 53 K | 53 K | 53 K | 40.4 K | 40.4 K | 40.4 K | 40.4 K | 23.1 K | 23.1 K | 23.1 K | 23.1 K | 6.66 K | 10.2 K | 14.2 K | 14.4 K | 8 K | 8 K | 8 K | 8 K | 5 K | 5 K | 5 K | 5 K | 5 K | 5 K | 5 K | 5 K | 69 K | 69 K | 69 K | 69 K | - | - | - | - | - | - | - | - |
Retained Earnings |
-421 M | -263 M | -185 M | -183 M | -180 M | -178 M | -175 M | -172 M | -168 M | -164 M | -161 M | -157 M | -154 M | -146 M | -142 M | -131 M | -128 M | -120 M | -115 M | -112 M | -108 M | -108 M | -108 M | -108 M | -82.5 M | -82.5 M | -82.5 M | -82.5 M | -63.1 M | -63.1 M | -63.1 M | -63.1 M | -53 M | -54.8 M | -54.8 M | -54.8 M | -47 M | -47 M | -47 M | -47 M | -40.5 M | -40.5 M | -40.5 M | -40.5 M | -35.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
45.2 M | 3.14 M | 3.44 M | 5.87 M | 4.97 M | 7.5 M | 10.6 M | 10.6 M | 14.4 M | 18.2 M | 21 M | 25.1 M | 25.7 M | 33.2 M | 36.5 M | 25.7 M | 43.8 M | 51.2 M | 56.9 M | 39.7 M | 13.1 M | 13.1 M | 13.1 M | 13.1 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 3.71 M | 3.71 M | 3.71 M | 3.71 M | 3.62 M | 3.62 M | 3.62 M | 3.62 M | 2.81 M | 2.81 M | 2.81 M | 2.81 M | 5.63 M | 5.63 M | 5.63 M | 5.63 M | 901 K | 901 K | 901 K | 901 K | 593 K | 593 K | 593 K | 593 K | 370 K | 370 K | 370 K | 370 K | 446 K | 446 K | 446 K | 446 K |
Cash and Cash Equivalents |
6.93 M | 182 K | 506 K | 3.09 M | 612 K | 2.96 M | 5.28 M | 4.73 M | 8.73 M | 11.9 M | 14.8 M | 18.6 M | 22.1 M | 25.4 M | 28.2 M | 25.1 M | 28.2 M | 41.8 M | 44.9 M | 27.3 M | 678 K | 678 K | 678 K | 678 K | 151 K | 151 K | 151 K | 151 K | 162 K | 162 K | 162 K | 162 K | 766 K | 766 K | 766 K | 766 K | 1.76 M | 1.76 M | 1.76 M | 1.76 M | 4.86 M | 4.86 M | 4.86 M | 4.86 M | 16.4 K | 16.4 K | 16.4 K | 16.4 K | 102 K | 102 K | 102 K | 102 K | 13.1 K | 13.1 K | 13.1 K | 13.1 K | 123 K | 123 K | 123 K | 123 K |
Book Value |
40.3 M | -77.4 M | -1.65 M | -146 K | -203 K | 1.97 M | 4.09 M | 4.05 M | 8.27 M | 11.7 M | 14.7 M | 18.6 M | 21.8 M | 29.6 M | 33.5 M | 22.9 M | 40.3 M | 47.8 M | 53.1 M | 35.5 M | 2.64 M | 2.64 M | 2.64 M | 2.64 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 53.5 K | 53.5 K | 53.5 K | 53.5 K | 2.69 M | 2.69 M | 2.69 M | 2.69 M | 924 K | 924 K | 924 K | 924 K | 4.11 M | 4.11 M | 4.11 M | 4.11 M | -5.52 M | -5.52 M | -5.52 M | -5.52 M | -3.22 M | -3.22 M | -3.22 M | -3.22 M | -3.3 M | -3.3 M | 370 K | 370 K | 446 K | 446 K | 446 K | 446 K |
Total Shareholders Equity |
40.3 M | -77.4 M | -1.65 M | -146 K | -203 K | 1.97 M | 4.09 M | 4.05 M | 8.27 M | 11.7 M | 14.7 M | 18.6 M | 21.8 M | 29.6 M | 33.5 M | 37.2 M | 40.3 M | 47.8 M | 53.1 M | 35.5 M | 2.64 M | 2.64 M | 2.64 M | 2.64 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 53.5 K | 53.5 K | 53.5 K | 53.5 K | 2.69 M | 2.69 M | 2.69 M | 2.69 M | 924 K | 924 K | 924 K | 924 K | 4.11 M | 4.11 M | 4.11 M | 4.11 M | -5.52 M | -5.52 M | -5.52 M | -5.52 M | -3.22 M | -3.22 M | -3.22 M | -3.22 M | -3.3 M | -3.3 M | -3.3 M | -3.3 M | -2.7 M | -2.7 M | -2.7 M | -2.7 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Predictive Oncology , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Medical instruments
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
STAAR Surgical Company
STAA
|
$ 24.16 | 2.94 % | $ 1.2 B |  USA |
 |
Stereotaxis
STXS
|
$ 1.3 | 0.36 % | $ 118 M | USA |
 |
Microbot Medical
MBOT
|
$ 1.5 | 4.17 % | $ 68.7 M |  Israel |
 |
Retractable Technologies
RVP
|
$ 0.7 | 1.29 % | $ 21 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 10.99 | 0.48 % | $ 2.19 B | USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
Utah Medical Products
UTMD
|
$ 69.16 | 0.55 % | $ 224 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 137.0 | 0.38 % | $ 6.11 B | USA |
 |
West Pharmaceutical Services
WST
|
$ 337.75 | 0.03 % | $ 24.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Alcon
ALC
|
$ 69.12 | 0.3 % | $ 34.1 B |  Schweiz |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
AngioDynamics
ANGO
|
$ 15.22 | 0.13 % | $ 632 M | USA |
 |
AtriCure
ATRC
|
$ 53.73 | 4.29 % | $ 2.57 B | USA |
 |
Baxter International
BAX
|
$ 24.86 | 1.02 % | $ 12.8 B | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 179.1 | 0.05 % | $ 51.5 B | USA |
 |
BioLife Solutions
BLFS
|
$ 35.38 | 0.37 % | $ 1.69 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
The Cooper Companies
COO
|
$ 67.69 | 1.31 % | $ 13.5 B | USA |
 |
electroCore
ECOR
|
$ 9.08 | 1.1 % | $ 77 K | USA |
 |
Glaukos Corporation
GKOS
|
$ 185.04 | 4.27 % | $ 10.6 B | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Haemonetics Corporation
HAE
|
$ 102.84 | 0.24 % | $ 4.85 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 7.95 | 1.62 % | $ 353 M | USA |
 |
ICU Medical
ICUI
|
$ 160.89 | 0.78 % | $ 3.96 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 11.89 | 0.74 % | $ 246 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 122.24 | 0.77 % | $ 3.91 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 350.16 | 0.28 % | $ 125 B | USA |
 |
Repro Med Systems
KRMD
|
$ 3.17 | 0.93 % | $ 146 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 79.59 | 0.22 % | $ 1.8 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.44 | 0.52 % | $ 36.1 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 87.38 | 1.16 % | $ 5.17 B | USA |
 |
Nephros
NEPH
|
$ 4.36 | 7.39 % | $ 46.3 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 26.81 | 0.73 % | $ 4.5 B | USA |
 |
OraSure Technologies
OSUR
|
$ 3.39 | 2.27 % | $ 249 M | USA |
 |
Pro-Dex
PDEX
|
$ 66.41 | 18.88 % | $ 214 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 48.79 | 3.85 % | $ 3.29 B | USA |
 |
ResMed
RMD
|
$ 221.05 | 0.04 % | $ 32.2 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
- | - | $ 9.59 B | USA |
 |
Repligen Corporation
RGEN
|
$ 168.53 | 0.55 % | $ 9.48 M | USA |
 |
STERIS plc
STE
|
$ 218.44 | 0.31 % | $ 21.5 B | USA |